GMED vs BSX
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 01, 2026
GMED
BSX
Investment Advisor Scores
BSX
AI Analyst Insights
Detailed Metrics Comparison
| Metric | GMED | BSX | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 17.9211 | 13.7174 | BSX |
| PEG Ratio | 1.7253 | 0.5706 | BSX |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 27.0% | 7.5% | GMED |
| Earnings Growth | 66.7% | 15.1% | GMED |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 50.7/100 | 55.0/100 | BSX |
| Profit Margin | 18.9% | 17.5% | GMED |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
GMED
DistributionPrice near a flattening SMA50 (slope -3.6%) with fading momentum, RSI 50
BSX
NeutralMixed signals - no dominant trend phase, RSI 58
Fundamentals Snapshot
| Metric | GMED | BSX |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 15.3 | 13.4 |
| Trailing P/E | 19.0 | 18.6 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.3% | 0.1% |
| Gross Margin | 0.7% | 0.7% |
| Operating Margin | 0.2% | 0.2% |
| EPS | 4.22 | 2.47 |
| Dividend Yield | — | — |